Nearly 50 million people worldwide live with dementia, of which Alzheimer’s disease is the major part. It’s estimated that by 2050, that population is going to reach more than 130 million.
Specialty formulation for Alzheimer’s disease
Geneware has taken a completely different approach to look at the pathology and mechanism of Alzheimer’s. Instead of looking at the molecular and cellular level specifically to the nerve system within the brain, Geneware looked through physiology and metabolism. Alzheimer’s is a metabolic disease with many similarities to and consequences after diabetes, so much so that Alzheimer’s disease is also called Type 3 diabetes, underlining an intimate and vicious link between these two diseases. That link is metabolism. Geneware has explored this link and engineered a specialty formulation that changes the metabolism to ameliorate the pathological status exist in Alzheimer’s condition. Geneware now has partnered with a healthcare provider (identity withdrawn due to confidentiality) to produce this formulation.